Phase I Safety and Tolerability Trial of Single and Repeat Doses of the RNA-based Adjuvant CV8102 Alone and in Combination With a Licensed Rabies Virus Vaccine in Healthy Adults
Phase of Trial: Phase I
Latest Information Update: 20 Feb 2019
Price : $35 *
At a glance
- Drugs Rabies vaccine (Primary)
- Indications Rabies
- Focus Adverse reactions; First in man; Proof of concept
- Sponsors CureVac
- 20 Feb 2019 Results published in the Vaccine
- 05 Jun 2018 Status changed from active, no longer recruiting to completed.
- 28 Jul 2016 Planned End Date changed from 1 Mar 2016 to 1 Oct 2016.